Day: March 10, 2025

SHAKOPEE, Minn., March 10, 2025 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2024. ($ in thousands, except per share data and percentages)         Three Months Ended December 31,   Twelve months ended December 31,  2024   2023   Change   2024   2023   ChangeNet revenues $11,978     $12,527     -4.4 %   $61,562     $61,437     0.2 %Net income(1) -$1,245     $1,364     -191.3 %   $2,113     $10,563     -80.0 %Adjusted EBITDA(2) $1,335     $2,051     -34.9 %   $10,234     $10,446     -2.0 %                       Basic EPS(1) -$0.25     $0.28     -189.3 %   $0.42     $2.15     -80.5 %Diluted EPS(1) -$0.25     $0.27     -192.6 %   $0.42     $2.13     -80.3 %                                   (1) ...

BOULDER, Colo., March 10, 2025 (GLOBE NEWSWIRE) — Gaia, Inc. (NASDAQ: GAIA), a conscious media and community company, reported financial results for the fourth quarter and full year ended December 31, 2024. Highlights:Q4 revenue increased 18% year over year. Full year revenue increased 12% to $90.4 million and EPS improved 19% year over year. Positive operating and free cash flow for both Q4 and the full year.“As planned, we have delivered positive free cash flow for both Q4 and the full year,” said Jirka Rysavy, Gaia’s Chairman. “Our price increase during second part of the year has already shown positive revenue impact with 18% revenue growth in the quarter. The price increase combined with investments in content, AI and community, shall further improve Gaia’s position.” “2024 was a year of strengthening our member base,...

— CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 — — Advancing four clinical programs for hematologic malignancies and autoimmune diseases — — $249.4 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2026 — BERKELEY, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2024 and reviewed recent pipeline progress. “Caribou is planning for two clinical data disclosures in the first half of 2025 as we advance the development of our off-the-shelf CAR-T cell therapies in oncology and autoimmune diseases,” said...

Achieved record fiscal first quarter revenue driven by higher price and volume in the Marketing & Distribution segment OXNARD, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in sourcing, producing, and distributing fresh Hass avocados, today reported its financial results for the fiscal first quarter ended January 31, 2025. Fiscal First Quarter 2025 Financial Overview:Total revenue increased 29% to $334.2 million compared to the same period last year Net income of $3.9 million, or $0.05 per diluted share, compared to $0.0 million, or $0.00 per diluted share, for the same period last year Adjusted net income of $7.1 million, or $0.10 per diluted share, compared to $6.7 million, or $0.09 per diluted share, for the same period last year Adjusted EBITDA...

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the American College of Cardiology Meeting Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 Recent $48.9 Million Financing Extends Cash Runway into mid-2026 SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the fourth quarter and full year ended December...

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. TSX-AD.UN CALGARY, Alberta, March 10, 2025 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (together, as applicable, with its subsidiaries, “Alaris” or the “Trust“) is pleased to announce its results for the three months and year ended December 31, 2024. The results are prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board. All amounts below are in Canadian dollars unless otherwise noted. In January 2024, Alaris determined that it met the definition of an investment entity, as defined by IFRS 10, Consolidated financial statements. This change in status has fundamentally changed how Alaris prepares, presents and...